Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet
By Bryan Koenig (February 22, 2019, 9:46 PM EST) -- Pay-for-delay deals staving off generic competition have become a favorite target for lawmakers eager to be seen combating soaring pharmaceutical costs and for antitrust enforcers who believe consumers are hurt when drug companies agree to postpone the introduction of generics. Promoting such competition for biological therapies may be next on Washington's list.
One therapy niche that has been free of pay-for-delay enforcement action so far is biologics, a novel type of treatment in which therapies are grown in a lab rather than chemically synthesized like traditional pharmaceuticals. Competition enforcers and private plaintiffs have yet to make any allegations that drug companies...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!